arrow_back Back Filing freshness 10-Q Q4 FY2026 SEC EDGAR

PRECISION BIOSCIENCES INC

DTIL
$7.51 ▲ +0.11 (+1.49%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
36 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

PRECISION BIOSCIENCES INC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth 5261.1%
Op. Margin 36.6%
ROIC 10.7%
FCF / Share None
Trailing P/E 2.9x
Price / Book 2.0x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

36-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$34.20M
↑ +5261.1%
Net Income Profit after all expenses
$20.13M
↑ +185.6%
Operating Margin Operating profit as % of sales
36.6%
↑ +143.7% 0th
FCF / Share Free cash flow per share
$-1.29
↓ -59.3%
Long-Term Debt Long-term obligations
$22.22M
— 0.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
12
Financial Health
17
Cash Quality
75

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 36 quarters